Rhythm Pharmaceuticals, Inc. specializes in the development of molecule therapies targeting metabolic pathways for the treatment of obesity, diabetes, and gastrointestinal functional disorders.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Rhythm Pharmaceuticals news
03.05.2022
Rhythm Pharmaceuticals' GAAP loss for 3 months of 2022 was $52.764 million, compared to a profit of $43.75 million in the previous year. Revenue increased 42.8 times to $1.498 million from $0.035 million a year earlier.
Source: 
ir.rhythmtx.com
ir.rhythmtx.com
01.03.2022
Rhythm Pharmaceuticals' GAAP loss for 2021 was $69.612 million, down 48% from $133.996 million the previous year. Revenue was $3.154 million. The company had no revenue a year earlier.
Source: ir.rhythmtx.com
ir.rhythmtx.com
06.12.2021
Rhythm Pharmaceuticals has granted RareStone exclusive rights to develop and commercialize setmelanotide in China. The drug is used to treat severe obesity and hyperphagia. Rhythm will receive $12 million in cash and stock in RareStone, and will be entitled to receive up to $63.5 million, if certain development milestones are reached, and royalties on sales.
Source: ir.rhythmtx.com
ir.rhythmtx.com
02.11.2021
Rhythm Pharmaceuticals' GAAP loss for 9M 2021 was $26.746 million, down 3.7 times from $99.099 million in the previous year. Revenues were $1,337 million. A year earlier the company had not received revenues.
Source: ir.rhythmtx.com
ir.rhythmtx.com
General information
| Company name | Rhythm Pharmaceuticals |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116 857-264-4280 |
| Mailing address | 222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116 |
| Website | www.rhythmtx.com |
| Information disclosure | www.sec.gov |
English (US) 